Abstract:Metabolic dysfunction–associated steatotic liver disease (MASLD) is a prevalent condition with a broad spectrum defined by liver biopsy. This gold standard method evaluates three features: steatosis, activity (ballooning and lobular inflammation), and fibrosis, attributing them to certain grades or stages using a semiquantitative scoring system. However, liver biopsy is subject to numerous restrictions, creating an unmet need for a reliable and reproducible method for MASLD assessment, grading, and staging. Noninvasive imaging modalities, such as magnetic resonance imaging (MRI), offer the potential to assess quantitative liver parameters. This review aims to provide an overview of the available MRI techniques for the three criteria evaluated individually by liver histology. Here, we discuss the possibility of combining multiple MRI parameters to replace liver biopsy with a holistic, multiparametric MRI protocol. In conclusion, the development and implementation of such an approach could significantly improve the diagnosis and management of MASLD, reducing the need for invasive procedures and paving the way for more personalized treatment strategies. Accepted Manuscript online: 28 May 2024 Article published online: 19 June 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the diagnosis and evaluation of Metabolic Dysfunction - Associated Steatotic Liver Disease (MASLD). Specifically, the paper explores the potential application of Multiparametric MRI (mpMRI) technology in evaluating MASLD, aiming to provide a comprehensive, non - invasive method to replace traditional liver biopsy. ### Main problems 1. **Limitations of traditional diagnostic methods**: - Although liver biopsy is the "gold standard", it has limitations such as invasiveness, small sample size, and semi - quantitative evaluation results, resulting in low consistency of paired biopsy samples, which affects the diagnosis and endpoint determination in late - stage MASLD clinical trials. 2. **The need for non - invasive imaging**: - A reliable and reproducible method is required to evaluate the grading and staging of MASLD, reduce the dependence on invasive procedures, and pave the way for personalized treatment strategies. ### Solutions - **Multiparametric MRI technology**: - **MRI - PDFF**: It is used to evaluate liver fat content and has the characteristics of whole - organ coverage and high sensitivity. - **MRE (Magnetic Resonance Elastography)**: It is used to evaluate liver stiffness and has high sensitivity and specificity for fibrosis. - **Gadoxetate - enhanced imaging**: It is used to evaluate hepatocyte function and extrahepatic water volume and can provide multiple physiological parameters. - **cT1 (Iron - corrected T1)**: It is used to evaluate fibrosis and inflammation. By correcting iron load and standardizing the influence of different scanners, it improves the accuracy of measurement. ### Goals - **Comprehensive evaluation**: Combine multiple MRI parameters to provide a comprehensive image of liver structure and function, covering multiple aspects such as steatosis, activity (ballooning and lobular inflammation), and fibrosis. - **Improve diagnosis and management**: Improve the diagnosis and management of MASLD through non - invasive methods, reduce the dependence on invasive procedures, and provide more personalized treatment plans for patients. ### Conclusion The development and implementation of a multiparametric MRI protocol can significantly improve the diagnosis and management of MASLD, reduce the need for invasive procedures, and pave the way for more effective personalized treatment strategies.

This Is What Metabolic Dysfunction–Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol

Evaluation of MRI proton density fat fraction in hepatic steatosis: a systematic review and meta-analysis

Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges

Application and research progress of magnetic resonance proton density fat fraction in metabolic dysfunction-associated steatotic liver disease: a comprehensive review

Comparing imaging modalities in the assessment of fibrosis in metabolic dysfunction‐associated steatotic liver disease

Novel Quantitative Liver Steatosis Assessment Method With Ultrasound Harmonic Imaging

Evaluation of Liver Fibrosis through Noninvasive Tests in Steatotic Liver Disease

A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease

Non-invasive testing in metabolic dysfunction-associated steatotic liver disease

Quantitative MRI for Monitoring Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Test–Retest Repeatability Study

Omics-based biomarkers as useful tools in metabolic dysfunction-associated steatotic liver disease clinical practice: How far are we?

A meta-analysis on the diagnostic performance of magnetic resonance imaging and transient elastography in nonalcoholic fatty liver disease

Detecting altered hepatic lipid oxidation by MRI in an animal model of MASLD

Accuracy of controlled attenuation parameter for liver steatosis in patients at risk for metabolic dysfunction-associated steatotic liver disease using magnetic resonance imaging: a systematic review and meta-analysis

Specific metabolic impairments indicate loss of sustained liver improvements in metabolic dysfunction-associated steatotic liver disease treatment

Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

Applying Proteomics in Metabolic Dysfunction-Associated Steatotic Liver Disease: from Mechanism to Biomarkers

Accuracy of Non‐Invasive Imaging Techniques for the Diagnosis of MASH in Patients With MASLD: A Systematic Review

Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD

Noninvasive tools for the assessment of fibrosis in metabolic dysfunction-associated steatotic liver disease

Multiparametric ultrasound imaging for early‐stage steatosis: Comparison with magnetic resonance imaging‐based proton density fat fraction